Annals of Otolaryngology Head and Neck Surgery (ISSN 2835-7132) | Volume 5, Issue 2 | Research Article | Open Access
Abdus Sami*
Abdus Sami*, G.S. Hashmi, Sumbul Jameel, Tabishur Rahman, Mohammad Danish
Department of Oral and Maxillofacial Surgery, Dr. Ziauddin Ahmad Dental College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
*Correspondence to: Abdus Sami
Fulltext PDFAim: To retrospectively analyze the clinical presentation, risk factors, radiological findings and management strategies in patients diagnosed with rhinomaxillary and mandibular mucormycosis.
Methods: This retrospective study included 16 patients with a documented history of COVID-19 infection and histopathologically confirmed rhinomaxillary or mandibular mucormycosis who presented to our institute between June 2021 and May 2023. Clinical features, comorbidities, radiological findings, treatment modalities, and follow-up outcomes were recorded and analyzed.
Results: The study population comprised 11 males and 5 females, with a mean age of 49.7 years. Diabetes mellitus was the most common comorbidity (69%), followed by hypertension and hypothyroidism. Ten patients required hospitalization during COVID-19 illness, and corticosteroids were administered in eight cases. Common clinical features included facial swelling, infraorbital paresthesia, visual disturbances, and intraoral findings such as tooth mobility and pus-discharging sinuses. Radiological evaluation demonstrated maxillary bone erosion and paranasal sinus involvement in all patients, with one case showing mandibular involvement. All patients underwent aggressive surgical debridement followed by systemic antifungal therapy. Postoperative complications included oroantral fistula formation in six patients, one mortality, and one recurrence.
Conclusion: Rhinomaxillary mucormycosis is an important post–COVID-19 complication, particularly in patients with diabetes mellitus and a history of corticosteroid use. Early diagnosis, aggressive surgical intervention, and appropriate antifungal therapy are essential for improving clinical outcomes and reducing disease-related morbidity.
COVID-19, Mucormycosis, Rhinomaxillary, Amphotericin B, Corticosteroids
Abdus Sami, G.S. Hashmi, Sumbul Jameel, Tabishur Rahman, Mohammad Danish. Beyond the Survival: A Retrospective analysis of Clinical course and Outcomes of Post-COVID associated Rhino-Maxillary Mucormycosis. Annal of Otol Head and Neck Surg. 2026;5(2):1-15.